Please help our Preclinical & Drug Discovery CRO with our ultimate goal: to help bring new and improved biologically relevant treatment options to patients.
Are you willing to further scientific research and new drug development to benefit patients? If so, you may wish to consider becoming part of our human tissue network.
If you are either:
— then we would like to discuss options with you.
At REPROCELL, we work on an individual basis with all our sites to implement the best ethical and logistical process for you, your internal systems, and our tissue needs. All tissues are used to investigate the safety or efficacy of a new drug compound or a drug combination on behalf of our pharmaceutical sponsors. Importantly, our assays provide valuable human-based data crucial to the decision-making process on progressing a novel treatment through development to the clinic. All we require from a partner tissue site is access to ethically consented fresh human tissues and a suitable collection process.
To obtain the highest quality data for drug development, our researchers only work with fresh human tissue samples. While this represents a logistical challenge for us, it ensures that donor tissue maintains functionality throughout the experimental period, providing the most biologically relevant data for analysis. Fresh tissues can be used across all stages of the drug development process, from target identification to clinical troubleshooting. Some of the tissue types that we have an increased demand for include:
An inability to obtain the necessary tissues can delay vital research necessary for novel drug development. This includes drugs that are undergoing clinical trial, where researchers are using human tissue testing to troubleshoot clinical side effects. While clinicians may have concerns about how willing patients are to consent to donation, studies show that they are likely to donate tissue for research and the greater good if asked. If you have any questions about the donation process, you can contact our clinical alliance team using the form below.
Fresh colon tissues can be used to test a range of drug characteristics ex vivo, including drug absorption, anti-inflammatory properties, and effects on gastrointestinal (GI) motility. We use both healthy and inflammatory bowel disease (IBD) tissues to generate translational pharmacological data.
Our models that use fresh colon tissue:
Diseased and healthy fresh skin tissue can be used to measure changes in inflammatory mediators in response to topical or systemic drugs. Our team commonly test experimental compounds on samples from healthy donors and those with atopic dermatitis, psoriasis, and acne vulgaris. These tissues are typically residual to cosmetic procedures or obtained through special clinical collections.
Respiratory structures contained in fresh lung tissues can be used to measure the effectiveness of test articles with a range of therapeutic properties. For example, Precision Cut Lung Slices (PCLS) can be used to investigate the efficacy of anti-inflammatory drugs while contractility can be investigated in airways of different sizes.
Our assays using fresh lung tissue include:
Latest in Drug Discovery
Mapping the Competitive Landscape of Human Tissue-Based Drug Discovery
Explore how REPROCELL leads in human tissue-based drug discovery, addressing market gaps and offering innovative, disease-relevant solutions for better therapeutic outcomes.
02 April 2026
Donor Variability in Ex Vivo Human Tissue Studies: Challenge, Feature, or Translational Advantage
Explore how donor variability in ex vivo human tissue studies enhances translational research by providing insights into patient heterogeneity and improving drug discovery.
12 March 2026
.jpg?width=756&height=425&name=Untitled%20design%20(10).jpg)
Preserving the Microenvironment-Advances in Ex Vivo Colonic Tissue Culture for IBD Drug Discovery
Advances in ex vivo colonic tissue culture preserve the microenvironment, enhancing IBD drug discovery by maintaining native tissue architecture and immune complexity for more predictive research models.
26 February 2026